Acorda Therapeutics Inc ACOR:NASDAQ (Common Stock)

LastDaily Change / % ChangeDividend YieldVolumeAvg Volume (10 day)
27.05 0.40   1.50%--655,780551.4K
Market data is delayed by at least 15 minutes.
Summary chart showing the current equity's performance of over the past 1 days
  • Advanced Charts
  • Embed the above chart in your blog or website

    Customize, copy, and then paste the generated code into your website.

Previous close 10/18/2017 (03:59 PM 10/18/2017 Eastern Standard Time)

Latest News Headlines for Acorda Therapeutics Inc

Acorda Third Quarter 2017 Update: Webcast/Conference Call Scheduled for October 31, 2017

ARDSLEY, N.Y.--(BUSINESS WIRE)--October 10, 2017-- Acorda Therapeutics, Inc. (Nasdaq:ACOR) will host a conference call and webcast to report its third quarter 2017 financial results and pipeline updates on Tuesday, October 31 at 8:30 a.m. ET.

View more recent headlines

Peers Information HelpACOR Acorda Therapeutics Inc vs. Peers

Acorda Therapeutics Inc
Medpace Holdings Inc
Genomic Health, Inc.
China Biologic Products Holdings Inc
PDL BioPharma Inc
Acorda Therapeutics Inc
Medpace Holdings Inc
Genomic Health, Inc.
China Biologic Products Holdings Inc
PDL BioPharma Inc
Acorda Therapeutics Inc
Medpace Holdings Inc
Genomic Health, Inc.
China Biologic Products Holdings Inc
PDL BioPharma Inc
Compare these stocks

Latest Annual and Quarterly SEC Filings

More Filings

This report contains detailed information about the company's business finances and management.


Quarterly reports contain financial statement, a discussion from management and a list of company events (stock splits, acquisitions, etc.)

Company Background

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.


collapse, right-facing arrow indicating collapsed view of sectionOverview

A table providing an overview of the stock
Bid | Size-- | --
Ask | Size-- | --
Price Open26.70
Previous Close27.05
Day High27.4034
Day Low26.60
52 Week High3/9/2017 | 33.00
52 Week Low6/1/2017 | 13.60
% Off 52 Week High-18.03%
% Off 52 Week Low98.90%
Beta (5 Yr)1.68
Volatility Avg10/18/2017 | 61.16
10-Day Avg. Volume551,407
Market data is delayed by at least 15 minutes.

collapse, right-facing arrow indicating collapsed view of sectionFundamentals

A table providing the fundamentals of the stock
EPS (TTM)6/30/2017 | -0.94
P/E Ratio6/30/2017 | --
Market CapSmall Cap | 1.26B
Shares Outstanding46.65M

collapse, right-facing arrow indicating collapsed view of sectionDividends

A table providing information about the dividends of the stock
Dividend Yield--
Dividend Announcement--
Date of Record--
Payable-- - --
Payable Date--

collapse, right-facing arrow indicating collapsed view of sectionShare Statistics

A table providing statistics about shares of the stock
Shares Short8.22M
Short Ratio10.7
Short % of Float17.97%
As of 9/15/2017
The performance data quoted represents past performance. Past performance does not guarantee future results. Current performance may be lower or higher than the performance quoted. Investment return and principal value of an investment will fluctuate and when redeemed, the investment may be worth more or less than their original cost.
The research, tools, and information provided will not include every security available to the public.